^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Potential molecular biomarkers of response to eribulin in patients with leiomyosarcoma

Published date:
05/15/2020
Excerpt:
In ERI-treated patients, the presence of ATRX mutations was more frequently observed in patients progressing on ERI (7/20 in patients with PD vs . 1/20 in group with disease control; p=0.0435) . The presence of ATRX mutation had a negative impact on both PFS and OS . TP53 mutations were associated with longer PFS, and these mutations were more frequently observed in patients achieving disease control, although this was not statistically significant (11/20 vs . 5/20).